Dr. Roberto Cosme Heros, MD

Dr. Heros practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Heros' NPI, 1962466987, was assigned on April 14, 2006. Dr. Heros graduated from University of Tennessee Health Science Center College of Medicine - Memphis in 1968. Dr. Heros holds Florida license ME0075208.

Dr. Heros' primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Heros' primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heros practices. Vendor and product names are available with a free account.

Neurological surgery is Dr. Heros' primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Heros is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Heros' licenses on file in 4 states: Florida, Minnesota, Pennsylvania and Ohio.

CMS data shows 22 Medicare services from Dr. Heros across 1 procedure code in 2024, all of them office visits, for 29 Medicare patients. Medicare paid $659 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 29 Medicare patients who saw Dr. Heros in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. 48% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heros' median patient age at 69, with 64% women.

In 2024, Dr. Heros wrote 18 Medicare Part D claims. 94% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $5 in total drug cost. In 2017, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Heros for performance year 2024, reported as part of a group. Dr. Heros accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 139 papers to Dr. Heros, published from 2005 to 2016. 2013 was the busiest year, with 8. The most frequent topics are Intracranial Aneurysm, Cerebral Angiography and Intracranial Arteriovenous Malformations. Dr. Heros has published most often in J Neurosurg. Dr. Heros' most frequent co-authors are Mohamed Samy Adel Elhammady, MD, Paul J. Camarata, MD and Jacques J. Morcos, MD.

Dmand AI links Dr. Heros to 2 clinical trials. Conditions studied include Glioblastoma and Astrocytoma.

CMS Open Payments shows 12 general payments to Dr. Heros from 9 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $247.

Dmand AI lists 13 awards for Dr. Heros, most recently America's Top Doctors in 2014.

Dr. Heros graduated from University of Tennessee Health Science Center College of Medicine - Memphis in 1968. Dr. Heros is a member of AANS, ACS and CNS.

Dr. Heros is in network with 10 carriers, including Elevance, United Healthcare and Molina. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.